Navigation Links
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
Date:1/16/2008

FDA evaluates clinical protocols and may achieve agreement with sponsors and applicants on the design and size of the studies and clinical trials that can be used for approval of a drug. It is intended to provide assurance that if pre-specified trial results are achieved, they may serve as the primary basis for an efficacy claim in support of a new drug application. In general, these assessments are considered binding on the FDA as well as the sponsor unless public health concerns unrecognized at the time the SPA is entered into become evident or other new scientific concerns regarding product safety or efficacy arise.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from diseases that the company believes are not treated adequately by currently available medicines. The company uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history. The company has several proprietary product candidates in clinical development that address large market opportunities, including its two most advanced product candidates: UDB, a proprietary version of nebulized budesonide for the potential treatment of children with asthma, and MAP0004, a proprietary version of orally inhaled dihydroergotamine delivered by MAP Pharmaceuticals' proprietary Tempo inhaler for the potential treatment of migraine. In addition to UDB and MAP0004, MAP Pharmaceuticals has other proprietary product candidates in clinical development that also address large market opportunities, including a proprietary combination of an inhaled corticosteroid with a long-acting beta2-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
2. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
3. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
4. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
5. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
6. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
7. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
8. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
9. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
10. Cumberland Pharmaceuticals Announces Appointments
11. Pacira Pharmaceuticals Names David M. Stack CEO and President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... drink less sugar, according to a new study from ... enough, the study goes on to say, as all ... healthier at school , The research suggests a parent,s ... a child,s diet. , The study found Vancouver school ... per cent more likely to eat vegetables during the ...
(Date:9/18/2014)... 18, 2014 Relias Learning, the leader in ... services markets, today announced it has been named to the ... companies in America. , In the three-year period from 2010 ... almost 2,000 spots on the Inc. 5000 list to 1,025 ... , “The industries we serve continue to grow, and the ...
(Date:9/18/2014)... Gables, FL (PRWEB) September 18, 2014 ... a portion of proceeds to Feeding America Eastern Wisconsin. ... Days, 7 Ways to Save” with Turbana bananas and ... be two for $4 and Turbana bananas will be ... $1 for every two Fyffes pineapples that are purchased ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical Center ... EV™ for physicians — improving productivity ... solutions, Holyoke chose T-System’s solution because not only ... reimbursement, but also its ability to integrate with ... to capture emergency department, (ED) nurse documentation. , ...
(Date:9/18/2014)... Fit Body Boot Camp , an ... in the country and its popularity, as both a franchise ... enormously in 2014. , The company’s annual business conference, ... in Costa Mesa, CA on September 26 and 27, and ... Founder Bedros Keuilian, who is also considered the leading fitness ...
Breaking Medicine News(10 mins):Health News:Kids eat better if their parents went to college 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 3Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... arteries remains the leading cause of disease and death in ... Medicine researcher is helping to open new pathways toward treating ... of biomedical sciences, is researching mutant forms of a human ... grow new blood vessels to restore blood flow in damaged ...
... Source Endurance is pleased to,announce that it ... Sports and,Fitness of San Marcos Texas to collaborate ... encompass several areas of,collaboration including the sharing and ... training approaches, and deployment of one,of the first ...
... Children,s Research Hospital have demonstrated that children with ... can retain normal function in both kidneys by ... when preoperative scans suggest that the tumors are ... St. Jude patients with bilateral Wilms tumor exhibiting ...
... Programs to be Marketed to Over 50,000 Members ... ... CANTEL MEDICAL,CORP. (NYSE: CMN ) and the National Safety Council ... prepare for the threat of a flu pandemic and similar,infectious diseases. The ...
... A SpaCapsule, Could Change The Outcome Of This ... Year,s Presidential Election, MIAMI, March 24 ... John McCain, Hillary Clinton and,Barack Obama,s stress levels are at an all ... city to city making,numerous public appearances. This can cause lack of sleep ...
... A study by a New York University dental research ... (gum) disease are more likely to develop gestational diabetes ... , The study, led by Dr. Ananda P. Dasanayake, ... NYU College of Dentistry, followed 256 women at New ...
Cached Medicine News:Health News:FSU researcher's 'mutant' proteins could lead to new treatment for heart disease 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 3Health News:St. Jude study offers new hope for children with kidney tumors deemed inoperable 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 3Health News:Stress On The Campaign Trail, One Issue All The Candidates Agree On 2Health News:NYU dental researchers find evidence of periodontal disease leading to gestational diabetes 2
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... , BOCA RATON, Fla., Nov. 16 CPG has ... Management (PLM) Release 9.3 at Avema Pharma Solutions, a division ... operation of pharmaceutical, over-the-counter (OTC), and nutritional solid-dose products based ... live at Avema on September 28, 2009. "As a contract ...
... , JAMAICA PLAIN, Mass., Nov. 16 ... presentation today at the AACR-NCI-EORTC International Conference Molecular Targets ... efficiently penetrates the blood brain barrier and may be ... Olaf van Tellingen, Ph.D. of The Netherlands Cancer Institute, ...
Cached Medicine Technology:CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions 2Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 2Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 3
Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
Delicate strong curved serrated tips. Serrated handle with dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
Medicine Products: